Mechanism governing reversal of multidrug resistance in human breast carcinoma cells by chelerythrine.
- Author:
Cao ZHE
1
;
Wang LI-JUAN
;
Wu Ming HUI
;
Jiao YU
;
Sun Yu JIE
;
Guo JUN
Author Information
- Publication Type:Journal Article
- MeSH: ATP Binding Cassette Transporter, Sub-Family B; ATP-Binding Cassette, Sub-Family B, Member 1; metabolism; Benzophenanthridines; pharmacology; Breast Neoplasms; metabolism; pathology; Cell Line, Tumor; Drug Resistance, Multiple; drug effects; Drug Resistance, Neoplasm; drug effects; Female; Humans
- From: Acta Academiae Medicinae Sinicae 2011;33(1):45-50
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo explore the mechanism governing the reversal of multidrug resistance in human breast carcinoma cells by chelerythrine.
METHODSReverse transcription-polymerase chain reaction (RT-PCR) and Western blot were used to determine the expressions of protein kinase Cα (PKCα) and multidrug resistance-related genes ABCG2, ABCC1, MDR1, and P-glycoprotein (P-gp) in MCF-7Taxol cells after treatment with chelerythrine and phorbol-12-myristate-13-acetate (PMA). Also, the antitumor effect of PMA or chelerythrine and effects of PKCα activator or inhibitor in combination with paclitaxel or adriamycin on multidrug resistance in MCF-7Taxol cells were evaluated by MTT.
RESULTSRT-PCR or Western blot showed that the expressions of MDR1 and P-gp were significantly higher in MCF-7Taxol cells exposed to PMA stimuli (both P0.05).
CONCLUSIONPKCα inhibitor chelerythrine can reverse multidrug resistance in breast carcinoma cells by inhibiting the expressions of MDR1 and P-gp expression in vitro.
